Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques
- 1 February 2003
- journal article
- basic science
- Published by Wolters Kluwer Health in AIDS
- Vol. 17 (3) , 301-309
- https://doi.org/10.1097/00002030-200302140-00003
Abstract
Background: The majority of infants infected through maternal transmission acquire the virus during birth or postpartum through breastfeeding: mucosal exposure is considered to be a major route of infection. Objectives: To develop passive immunization with human neutralizing monoclonal antibodies (mAbs) against mother-to-child transmission of HIV during delivery and through breastfeeding. Design: An oral challenge model in newborn rhesus macaques mimicked peri- and postpartum virus transmission. Methods: Neonatal rhesus macaques were challenged orally with the highly pathogenic, chimeric simian–human immunodeficiency virus SHIV89.6P and given post-exposure prophylaxis with a quadruple combination of neutralizing human mAbs, IgG1b12, 2G12, 2F5, and 4E10, directed against conserved epitopes of HIV envelope glycoproteins. Control animals were virus challenged but left untreated. All infants were followed prospectively for signs of viremia and immunodeficiency. Results: Two out of four macaque infants treated with neutralizing mAbs showed no evidence of infection; the other two maintained normal CD4 T cell counts. In contrast, all control animals became highly viremic and had profound CD4 T cell losses; three out of four died from AIDS within 1.5–6 weeks of the challenge. Conclusions: Passive immunization with this quadruple neutralizing mAbs combination may represent a promising approach to prevent peri- and postnatal HIV transmission. Furthermore, the epitopes recognized by the four neutralizing mAbs are key determinants to achieve complete protection and represent important targets against which to develop active, antibody-response-based AIDS vaccines.Keywords
This publication has 53 references indexed in Scilit:
- Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trialThe Lancet, 2002
- DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virusJournal of Medical Primatology, 2002
- Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1Journal of Virology, 2001
- A Potent Cross-Clade Neutralizing Human Monoclonal Antibody against a Novel Epitope on gp41 of Human Immunodeficiency Virus Type 1AIDS Research and Human Retroviruses, 2001
- Immunization with Recombinant Canarypox Vectors Expressing Membrane-Anchored Glycoprotein 120 Followed by Glycoprotein 160 Boosting Fails to Generate Antibodies That Neutralize R5 Primary Isolates of Human Immunodeficiency Virus Type 1AIDS Research and Human Retroviruses, 2000
- Characterization of lymphocyte subsets in rhesus macaques during the first year of lifeEuropean Journal of Haematology, 2000
- Sensitive and Robust One-Tube Real-Time Reverse Transcriptase-Polymerase Chain Reaction to Quantify SIV RNA Load: Comparison of One- versus Two-Enzyme SystemsAIDS Research and Human Retroviruses, 2000
- Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and their childrenClinical and Experimental Immunology, 1993
- Antibodies Mediating Cellular Cytotoxicity and Neutralization Correlate with a Better Clinical Stage in Children Born to Human Immunodeficiency Virus-Infected MothersThe Journal of Infectious Diseases, 1990
- Intravenous immune globulin in symptomatic paediatric human immunodeficiency virus infectionEuropean Journal of Pediatrics, 1988